Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1

Molecular Pharmacology

Volumn 76, Issue 1, 2009, Pages 81-90

  Li, Jun ^a,d,e   Wang, Yun ^b   Yang, Chaozhe ^a   Wang, Pengfei ^b   Oelschlager, Denise K ^a   Zheng, Yong ^d,e   Tian, De An ^d   Grizzle, William E ^a   Buchsbaum, Donald J ^c   Wan, Mei ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c The University of Alabama at Birmingham   (United States)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e SHIHEZI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CURCUMIN; GEMCITABINE; JUN ACTIVATION DOMAIN BINDING PROTEIN 1; POLYETHYLENE GLYCOL CONJUGATED CURCUMIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOSIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN TARGETING;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DEOXYCYTIDINE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PANCREATIC NEOPLASMS; PEPTIDE HYDROLASES; POLYETHYLENE GLYCOLS;

EID: 67649876052     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.054551     Document Type: Article

References (38)

1. Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C, and Dubiel W (2001) COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 20:1630-1639. (Pubitemid 32299400)
2. Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC, Head DR, Hugh TB, Sutherland RL, and Henshall SM (2002) DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 20:4531-4542. (Pubitemid 35402956)
3. Brand R and Mahr C (2005) Risk factors for pancreatic adenocarcinoma: are we ready for screening and surveillance? Curr Gastroenterol Rep 7:122-127. (Pubitemid 40796697)
4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413.
5. Caliceti P and Veronese FM (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55:1261-1277. (Pubitemid 37464561)
6. Farrow B, Evers BM (2004) Inflammation and the development of pancreatic cancer. Surg Oncol Oxf 10:153-159.
7. Fukumoto A, Ikeda N, Sho M, Tomoda K, Kanehiro H, Hisanaga M, Tsurui Y, Tsutsumi M, Kato JY, and Nakajima Y (2004) Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. Oncol Rep 11:277-284.
8. Fukumoto A, Tomoda K, Yoneda-Kato N, Nakajima Y, and Kato JY (2006) Depletion of Jab1 inhibits proliferation of pancreatic cancer cell lines. FEBS Lett 580:5836-5844. (Pubitemid 44584281)
9. Goel A, Jhurani S, and Aggarwal BB (2008) Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res 52:1010-1030.
10. Greenwald RB, Gilbert CW, Pendri A, Conover CD, Xia J, and Martinez A (1996) Drug delivery systems: water soluble Taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J Med Chem 39:424-431. (Pubitemid 26037894)
11. Greenwald RB, Choe YH, McGuire J, and Conover CD (2003) Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 55:217-250. (Pubitemid 36135917)
12. Hidaka H, Ishiko T, Furuhashi T, Kamohara H, Suzuki S, Miyazaki M, Ikeda O, Mita S, Setoguchi T, and Ogawa M (2002) Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the cell surface: impact on human pancreatic carcinoma cell growth by autocrine regulation. Cancer 95: 1206-1214. (Pubitemid 35013053)
13. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, and Kern SE (2001) Molecular pathology of pancreatic cancer. Cancer J 7:251-258.
14. Hua Z, Zhang YC, Hu XM, and Jia ZG (2003) Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J Gastroenterol 9:2764-2767. (Pubitemid 38054456)
15. Hui YF and Reitz J (1997) Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 154:162-170. (Pubitemid 27058210)
16. Hsu CH and Cheng AL (2007) Clinical studies with curcumin. Adv Exp Med Biol 595:471-480.
17. Kamada H, Tsutsumi Y, Yamamoto Y, Kihira T, Kaneda Y, Mu Y, Kodaira H, Tsunoda SI, Nakagawa S, and Mayumi T (2000) Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice. Cancer Res 60:6416-6420. (Pubitemid 30952146)
18. Kim BC, Lee HJ, Park SH, Lee SR, Karpova TS, McNally JG, Felici A, Lee DK, and Kim SJ (2004) Jab1/CSN5, a component of the COP9 signalosome, regulates transforming growth factor beta signaling by binding to Smad7 and promoting its degradation. Mol Cell Biol 24:2251-2262. (Pubitemid 38325982)
19. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, and Grossman AB (2002) Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 87:2635-2643. (Pubitemid 34655325)
20. Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P, Ho L, Evans DB, and Claret FX (2006) Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27 in pancreatic adenocarcinoma. Cancer Res 66: 8581-8589. (Pubitemid 44449172)
21. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, and Aggarwal BB (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products. Cancer Res 67:3853-3861. (Pubitemid 46762173)
22. Lev-Ari S, Zinger H, Kazanov D, Yona D, Ben-Yosef R, Starr A, Figer A, and Arber N (2005) Curcumin synergistically potentiates the growth inhibitory and proapoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed Pharmacother 59 (Suppl 2):S276-S280. (Pubitemid 43303888)
23. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, and Kurzrock R (2004) Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101: 2351-2362. (Pubitemid 39458693)
24. Li L, Braiteh FS, and Kurzrock R (2005) Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104:1322-1331. (Pubitemid 41282806)
25. Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189-207. (Pubitemid 32520323)
26. Maheshwari RK, Singh AK, Gaddipati J, and Srimal RC (2006) Multiple biological activities of curcumin: a short review. Life Sci 78:2081-2087.
27. Naumann M, Bech-Otschir D, Huang X, Ferrell K, and Dubiel W (1999) COP9 signalosome-directed c-Jun activation/stabilization is independent of JNK. J Biol Chem 274:35297-35300. (Pubitemid 129512813)
28. Peng Z, Shen Y, Feng S, Wang X, Chitteti BN, Vierstra RD, and Deng XW (2003) Evidence for a physical association of the COP9 signalosome, the proteasome, and specific SCF E3 ligases in vivo. Curr Biol 13:R504-R505. (Pubitemid 36815244)
29. Seeger M, Kraft R, Ferrell K, Bech-Otschir D, Dumdey R, Schade R, Gordon C, Naumann M, and Dubiel W (1999) A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J 12: 469-478.
30. Sharma RA, Gescher AJ, and Steward WP (2005) Curcumin: the story so far. Eur J Cancer 41:1955-1968.
31. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tai Y, and Tokuda M (2001) Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res 7:4130-4135. (Pubitemid 34044637)
32. Sun Y, Wilson MP, and Majerus PW (2002) Inositol 1,3,4-trisphosphate 5/6-kinase associates with the COP9 signalosome by binding to CSN1. J Biol Chem 277: 45759-45764. (Pubitemid 35417552)
33. Tomoda K, Kubota Y, and Kato J (1999) Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398:160-165. (Pubitemid 29135455)
34. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, and Pastan I (2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci U S A 97:8548-8553. (Pubitemid 30639710)
35. Uhle S, Medalia O, Waldron R, Dumdey R, Henklein P, Bech-Otschir D, Huang X, Berse M, Sperling J, Schade R, et al. (2003) Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO J 22:1302-1312. (Pubitemid 36362694)
36. Wan M, Cao X, Wu Y, Bai S, Wu L, Shi X, Wang N, and Cao X (2002) Jab1 antagonizes TGF-β signaling by inducint Smad4 degradation. EMBO Reports 3:171-176. (Pubitemid 34213496)
37. β-TrCP1 controls Smad4 protein stability in pancreatic cancer cells. Am J Pathol 166:1379-1392.
38. Wang Z, Zhang Y, Banerjee S, Li Y, and Sarkar FH (2006) Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106:2503-2513. (Pubitemid 43787677)